PTK 0796 + linezolid + moxifloxacin
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Diseases, Infectious
Conditions
Skin Diseases, Infectious
Trial Timeline
Apr 4, 2009 → Apr 15, 2010
NCT ID
NCT00865280About PTK 0796 + linezolid + moxifloxacin
PTK 0796 + linezolid + moxifloxacin is a phase 3 stage product being developed by Novartis for Skin Diseases, Infectious. The current trial status is terminated. This product is registered under clinical trial identifier NCT00865280. Target conditions include Skin Diseases, Infectious.
What happened to similar drugs?
16 of 20 similar drugs in Skin Diseases, Infectious were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00865280 | Phase 3 | Terminated |
Competing Products
20 competing products in Skin Diseases, Infectious